CN115956078A - Akt3调节剂及其使用方法 - Google Patents

Akt3调节剂及其使用方法 Download PDF

Info

Publication number
CN115956078A
CN115956078A CN202180046157.6A CN202180046157A CN115956078A CN 115956078 A CN115956078 A CN 115956078A CN 202180046157 A CN202180046157 A CN 202180046157A CN 115956078 A CN115956078 A CN 115956078A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
akt3
aryl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180046157.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·克雷夫
M·姆科特奇扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Mooney LLC
Original Assignee
George Mooney LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Mooney LLC filed Critical George Mooney LLC
Publication of CN115956078A publication Critical patent/CN115956078A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Amplitude Modulation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180046157.6A 2020-05-08 2021-05-07 Akt3调节剂及其使用方法 Pending CN115956078A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021797P 2020-05-08 2020-05-08
US63/021,797 2020-05-08
PCT/US2021/031372 WO2021226510A2 (en) 2020-05-08 2021-05-07 Akt3 modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
CN115956078A true CN115956078A (zh) 2023-04-11

Family

ID=78468492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180046157.6A Pending CN115956078A (zh) 2020-05-08 2021-05-07 Akt3调节剂及其使用方法

Country Status (12)

Country Link
US (1) US20230181563A1 (https=)
EP (1) EP4146196A4 (https=)
JP (1) JP2023525758A (https=)
KR (1) KR20230019109A (https=)
CN (1) CN115956078A (https=)
AU (1) AU2021269065A1 (https=)
BR (1) BR112022022327A2 (https=)
CA (1) CA3182675A1 (https=)
IL (1) IL297596A (https=)
MX (1) MX2022014019A (https=)
PH (1) PH12022553026A1 (https=)
WO (1) WO2021226510A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525757A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター
AU2021266786A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046085A2 (en) * 2006-10-12 2008-04-17 Supergen, Inc. Quinoline derivatives for modulating dna methylation
US20090285772A1 (en) * 2007-10-12 2009-11-19 Supergen, Inc. Quinoline derivatives for modulating dna methylation
US20110160163A1 (en) * 2000-08-11 2011-06-30 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
US20150343028A1 (en) * 2014-04-17 2015-12-03 Georgia Regents Research Institute, Inc. Methods of modulating immune responses by modifying akt3 bioactivity
US20170202956A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Methods and Compositions for Inhibiting Akt3
US20170202829A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE461179T1 (de) * 2003-04-24 2010-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
CN110366749A (zh) * 2017-06-29 2019-10-22 惠普发展公司，有限责任合伙企业 可操作来具有充当主显示器的区域和充当辅显示器的区域的连续平面显示器
MX2020002611A (es) * 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160163A1 (en) * 2000-08-11 2011-06-30 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
WO2008046085A2 (en) * 2006-10-12 2008-04-17 Supergen, Inc. Quinoline derivatives for modulating dna methylation
US20090285772A1 (en) * 2007-10-12 2009-11-19 Supergen, Inc. Quinoline derivatives for modulating dna methylation
US20150343028A1 (en) * 2014-04-17 2015-12-03 Georgia Regents Research Institute, Inc. Methods of modulating immune responses by modifying akt3 bioactivity
US20170202956A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Methods and Compositions for Inhibiting Akt3
US20170202829A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
余元勋，鲍远程，王爱玲，王勇主编: "《中国疾病信号通路与靶向治疗学》", 31 May 2013, 合肥：安徽科学技术出版社, pages: 152 - 155 *

Also Published As

Publication number Publication date
CA3182675A1 (en) 2021-11-11
WO2021226510A9 (en) 2022-01-13
BR112022022327A2 (pt) 2023-01-03
WO2021226510A3 (en) 2021-12-16
JP2023525758A (ja) 2023-06-19
MX2022014019A (es) 2023-02-16
US20230181563A1 (en) 2023-06-15
IL297596A (en) 2022-12-01
AU2021269065A1 (en) 2022-12-15
KR20230019109A (ko) 2023-02-07
EP4146196A4 (en) 2024-06-26
EP4146196A2 (en) 2023-03-15
PH12022553026A1 (en) 2024-05-13
WO2021226510A2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
JP2023134731A (ja) 特異的ａｋｔ３活性化剤およびその使用
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
US20240316190A1 (en) Compositions and methods for selectively modulating tregs
JP2021512151A (ja) Ｂ７−ｈ４抗体およびその使用方法
US11603394B2 (en) Targeted effector proteins and uses thereof
RS60181B1 (sr) Terapeutska upotreba morfogenetskih proteina kosti
TW202142560A (zh) Ｇｌｐ－２衍生物之長效接合物
RS59344B1 (sr) Tatk-cdkl5 fuzioni proteini, sastavi, formulacije i njihova upotreba
US9707278B2 (en) Methods of modulating immune responses by modifying Akt3 bioactivity
CN115956078A (zh) Akt3调节剂及其使用方法
US9962423B2 (en) Protein particles comprising disulfide crosslinkers and uses
JP2019534300A (ja) プログラム細胞死リガンド１の腸管発現
CN115552013A (zh) 修饰的微核小体核心蛋白及其在核酸递送中的用途
US20140288010A1 (en) Compositions and Methods for Increasing Stem Cell Survival
US20250025559A1 (en) Irf-4 engineered t cells and uses thereof in treating cancer
HK40084846A (en) Akt3 modulators and methods of use thereof
CN110623979A (zh) 靶向cd19的嵌合抗原受体t细胞在自身免疫性疾病中的应用
WO2021243148A2 (en) Methods and compositions for treating alcoholic liver disease
RU2815372C2 (ru) Специфический активатор akt3 и его применение
WO2026008015A1 (en) Stanniocalcin 2 (stc2) and derivatives as anti-diabetic agents
Kakunuri a proliferation inducing ligand as a neuroregenerative treatment in multiple sclerosis
WO2024145365A2 (en) Compositions for the diagnosis, treatment, prevention, and alleviation of neurodegenerative and autoimmune disorders
TW202220974A (zh) 用於調節ａｋｔ３的方法及組合物
FR3147292A1 (fr) Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
JP2025540675A (ja) オクタデカニューロペプチド（ｏｄｎ）およびその合成誘導体を含む組成物、ならびに食物摂取、肥満、体重、吐き気および嘔吐の調節のための使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: Maryland, US

Applicant after: George Munet Co.

Address before: Maryland, US

Applicant before: George Mooney LLC

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084846

Country of ref document: HK